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ABSTRACT The current target groups for measles, mumps and rubella vaccination in the Islamic 
Republic of Iran are children at 12 months and 4–6 years. A study of the age-specific seroprevalence 
of antibodies against mumps in children aged 3–18 years in Shahrekord aimed to establish the need 
for booster vaccinations to cover non-immune children. Of 338 children, 19.8% were seronegative. 
Age-specific seronegativity was 33.3%, 20.5% and 4.6% in age groups 7–11, 12–14 and 15–18 years 
respectively. To obtain herd immunity, we suggest that for the next 5 years children aged 7–11 years 
entering guidance school are selected as the main group for vaccination.
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Séroprévalence des oreillons avant l’intégration de la vaccination anti-ourlienne dans le pro-
gramme élargi de vaccination iranien
RÉSUMÉ À l’heure actuelle, les groupes visés par la vaccination contre la rougeole, les oreillons et la 
rubéole en République islamique d’Iran sont les enfants âgés de 12 mois et ceux âgés de 4 à 6 ans. 
Une étude de la séroprévalence par âge des oreillons chez les enfants âgés de 3 à 18 ans a été menée 
à Shahrekord, dans le but de déterminer s’il y avait lieu de procéder à des vaccinations de rappel afin 
de protéger les enfants non immunisés. Sur 338 enfants, 19,8 % étaient séronégatifs. La séronégativité 
selon le critère de l’âge était respectivement de 33,3 %, 20,5 % et 4,6 % dans les groupes de sujets 
âgés de 7 à 11 ans, de 12 à 14 ans et de 15 à 18 ans. Pour obtenir une immunité collective, nous 
suggérons que pendant les 5 prochaines années, le principal groupe vacciné soit les enfants âgés de 
7 à 11 ans, avant leur entrée dans le second degré.
عينمتلل ع َّسولما نياريلإا جمانبرلا في هدض حيقلتلا جاردإ لبق فاكنلل ليصلما راشتنلاا ل َّدعم
ييرخ نمايلس ،نايبيبح ايور ،ناكزيوأ ديمج
 ةبصلحاو فاكنلاو ةبصلحا دض حيقلتلا ناريإ في نهارلا تقولا في عينمتلل ع َّسولما جمانبرلا فدهتسي :ةـصلالخا
 ل َّدعم لوح ةسارد نوثحابلا ىرجأ دقو .تاونس 6-4 ينب حوارـتي رمع في مث ًارهش 12 رمع في لافطلأل ةينالملأا
 ،دركرهش في ًاماع 18و 3 ينب مهرماعأ حوارـتت نيذلا لافطلأا في فاكنلا دادضلأ ينعم رمعب صالخا ليصلما راشتنلاا
 نم %19.8  نأ  نوثحابلا  دجو دقو .ينعَّنملما  يرغ لافطلأا ةيطغتل  ةز ِّزعم حيقلت  تاعرج لىإ ةجالحا ىدم ريرقتل
 ًاماع 11-7 ةيرمعلا ةئفلل %33.3 تناك ينعم رمعب ةصالخا لصلما ةيبلس نأو ،لصلما يـيبلس اوناك ًلافط 338 لصأ 
 ةعانم  لىع لوصحلل نوثحابلا  حرـتقيو .ًاماع 18-15  ةيرمعلا  ةئفلل  %4.6و ًاماع 14-12  ةيرمعلا  ةئفلل  %20.5و
 نولخدي نَّمم ،ًاماع 11و 7 ينب مهرماعأ حوارـتت نيذلا لافطلأا رايتخا متي نأ ةمداقلا سملخا تاونسلا في ب ْ ِّسلا
.حيقلتلل ةيسيئرلا ةعومجلما مهرابتعاب ،ةيهيجوتلا سرادلما ىوتسم
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Introduction
The selection of a target group for the Ex-
panded Programme on Immunization (EPI) 
is important [1]. The proportion of indi-
viduals in a population with doubtful pro-
tection (unvaccinated, nonresponders and 
low responders after primary vaccination) 
affects the chances of immunity reaching 
the 95% threshold that is necessary for herd 
immunity [2]. The population with doubtful 
protection must be a target group for vac-
cination and this can only be established by 
seroprevalence studies. A serological preva-
lence survey carried out in Izmir, Turkey to 
determine the antibody status of a popula-
tion aged 1–29 years against mumps infec-
tions reported that 20.1% were seronegative 
[3]. Previous studies carried out in Shiraz 
and Tehran in the Islamic Republic of Iran 
reported that 34.2% of the population of 
Shiraz and 82.3% of 5-year-olds and 29.4% 
of 10-year-olds in Tehran were seronegative 
[3,4]. On the basis of these results it can be 
seen there is a wide range of seronegativity 
among various age group which could affect 
the selection of a target group. 
After March 2004, vaccination against 
mumps, measles and rubella (MMR) was 
included in the Iranian EPI. The target 
groups for MMR vaccination are children at 
12 months and 4–6 years. There have been 
a limited number of studies determining the 
status of immunity against mumps in the Is-
lamic Republic of Iran [4,5], and we believe 
that there is insufficient evidence to justify 
the selection of these target groups. 
The main goal of this study was to estab-
lish the age-specific antibody seroprevalence 
against mumps in Iranian children aged 
3–18 years. The other aims were to obtain a 
baseline level of seroprevalence for repeated 
surveillance of current vaccination in the 
years following vaccination (at least in the 
region of the study) and also to establish the 
need for booster vaccinations to cover non-
immune children. The seronegative group 
could be helpful to evaluate the efficacy of 
mumps vaccine (manufactured in the Islamic 
Republic of Iran) in future studies.
Methods
This was a cross-sectional study conducted 
in 2004 in Shahrekord, the capital city of 
Chahar-Mahal and Bakhtiari province in the 
south-west of the Islamic Republic of Iran. 
Sample
The target group was children 3–18 years 
old. Based on limited previous studies [4,5], 
the estimated seronegativity of mumps 
among this population was 20%, and from 
this a sample size of 338 children was de-
termined. In the Islamic Republic of Iran, 
about 100% of children aged 7–18 years old 
go to school and about 95% of those aged 
3–6 years go to day care centres. 
We obtained the sampling frame from 
a local educational organization which 
included 158 schools (primary schools, 
guidance schools and high schools) and 100 
day care centres. Sampling was conducted 
by a 3-stage sampling method. In the first 
stage the total population of students was 
stratified according to day care centres, 
primary schools, guidance schools and high 
schools. Due to the lack of detailed previous 
prevalence studies on mumps, we used the 
probability proportional to size sampling 
technique, which means that samples were 
selected according to the proportion of chil-
dren in each stratum. Each stratum included 
several clusters (educational units), and 
in the 2nd stage, clusters were randomly 
selected. We selected 7 schools from the 
primary schools, guidance schools and high 
schools (3 units for girls and 4 units for boys, 
except for guidance schools where 2 units 
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were selected for boys). In the last stage, 
in each cluster, samples were randomly se-
lected from day care centres (n = 25, 9.2%), 
primary schools (n = 103, 30.5%), guidance 
schools (n = 151, 44.7%) and high schools 
(n = 59, 17.5%). There were 191 boys and 
147 girls, male to female ratio 1.3:1. 
Data collection 
Data collection was based on an interview 
questionnaire and serology testing. 
The parents of selected children were 
given a formal invitation to attend the school 
where their consent to participation was 
obtained. We did not encounter any refusals 
and, with the cooperation of the manager of 
schools, all selected children participated in 
the study. The parents were interviewed by 
our coinvestigator (a general practitioner) 
to collect data such as age, sex, history of 
previous exposure to mumps cases, history 
of previous mumps involvement and vac-
cination against mumps (these last 3 items 
were recorded as self-reported). Mumps 
was defined as a swelling of the parotid 
gland which lasted for at least 5–7 days ac-
companied by fever and difficulty eating. 
After filling in the questionnaire, 10 cm3 
of venous blood was taken from each child 
and centrifuged sera were frozen at –20 ºC. 
At the end of blood sampling, all tests were 
carried out simultaneously. IgG was meas-
ured using mumps IgG (ELISA) kits and 
instruments from Trinity Biotech Capita 
(Jamestown, United States of America). The 
quality control was done simultaneously 
with the measurement of samples. Based on 
the recommendation of the kit, negative and 
positive control numbers and the mean val-
ues were in an acceptable range. Based on 
the kit definition, the results were calculated 
as antigen–antibody ratios, and recorded as 
positive or negative. 
Ethical approval for the study was ob-
tained from the ethical committee of the 
University, and referred to the local educa-
tional organization for approval.
Statistical analysis
Statistical analysis was performed using 
the chi-square test and SPSS, version 11.5. 
P-value < 0.05 was considered statistically 
significant.
Results
Overall seroprevalence was 80.2% and 
therefore 19.8% of children tested were sen-
sitive to mumps infection (Table 1). 
The sex-specific seroprevalence was 
77.1% for females and 82.5% for males. 
Age-specific seroprevalence rose from 
66.7% for age group 7–11 years (primary 
school) to 79.5% for age group 12–14 years 
(guidance school) for 95.4% at age group 
Table 1 Age-specific seroprevalence of mumps IgG antibodies by sex and 
seropositivity 
Age group 
(years)
Serological reaction
Positive Negative Total
No. % No. % No. %
3–6 25 100.0 0 0.0 25 7.4
7–11 68 66.7 34 33.3 102 30.1
12–14 116 79.2 30 20.8 146 43.2
15–18 62 95.4 3 4.6 65 19.2
Total 271 80.2 67 19.8 338 100.0
P < 0.05.
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15–18 years (high school) (Table 1). The 
age group 3–6 years was 100% immune 
(Table 1). Using the chi-squared test, there 
was a significant difference between age 
and seroprevalence (P < 0.05).
There was a past history of mumps re-
ported in 259/338 children (76.6%). Serol-
ogy confirmed this in 76.4% of these cases. 
There was no reported history of mumps in 
79 children (23.4%). Nevertheless serology 
was positive in 92.4% of these cases (Table 
2). Using the chi-squared test, there was 
a significant difference in the agreement 
between serology and reported past history 
of mumps (P < 0.05)
There was reported past history of 
vaccination against mumps in 49 children 
(14.5%). The seroprevalence for mumps 
was significantly higher for vaccinated 
(42/49; 85.7%) than unvaccinated children 
(229/289; 79.2%) (Table 2). The chi-squared 
test showed a significant difference in the 
rate of agreement between serology and 
reported history of vaccination (P < 0.05).
There was reported past history of close 
contact with a case of mumps in 82/338 
children (24.3%). Serology agreed with the 
past history of close contact in 86.6% of 
such cases for mumps. There was no such 
history in 256 children (75.7%). Serology 
was positive in 78.1% of such cases (Table 
2). The chi-squared test showed no statisti-
cally significant difference in the rate of 
agreement between serology and reported 
past history of close contact with a mumps 
case. 
Discussion
Although MMR vaccination has been in-
cluded in the Iranian EPI since March 2004, 
it is not clear why the present age groups (12 
months and 4–6 years old) were selected for 
Table 2 Seroprevalence of mumps IgG antibodies by reported past history of mumps 
involvement, past history of mumps vaccination and past history of close contact 
with a mumps case
Variable Serological reaction
Positive Negative Total
No. % No. % No. %
Past history of mumps 
involvement 
 Positive history of mumps 198 76.4 61 23.5 259 76.6
 Negative history of mumps 73 92.4 6 7.6 79 23.4
P < 0.05
Past history of mumps 
vaccination
 Vaccinated 42 85.7 7 14.3 49 14.5
 Unvaccinated 229 79.2 60 20.8 289 85.5
P < 0.05
Past history of close contact 
with mumps case
 Positive history of contact 71 86.6 11 13.4 82 24.3
 Negative history of contact 200 78.1 56 21.9 256 75.7
P < 0.05
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mumps vaccination. One reason may be the 
convenience of the simultaneous adminis-
tration of measles and rubella. 
The method used in our study was ELISA 
testing, which was assumed to be suitable, 
specific and more sensitive than neutraliza-
tion and complement-fixation [6]. A Dutch 
study also indicated that indirect ELISA 
is a reliable method for measuring mumps 
virus-specific antibodies in population-
based studies [7].
Our study found a seronegativity rate of 
19.8%, which is lower than the rates report-
ed in previous Iranian studies (34.2% and 
29.4%) [4,5], but similar to the rate reported 
in Izmir, Turkey (20.1%) [3]. However, 
wide discrepancies can occur: for example, 
another Turkish study reported a rate of 
only 10.9% [8].
The sex-specific rates in our study 
showed a significant difference in sero-
negativity between females and males 
(29.9% and 17.5% respectively). In a study 
in Shiraz, 31.4% of girls and 35.8% of boys 
tested seronegative for mumps antibodies 
[4]. The rate of seronegativity in another 
study was also higher in males than females 
[8]. Reasons for the higher rates of seron-
egativity in males in Shiraz are unclear, 
although there may be different levels of 
outdoor activity (e.g. boys spending more 
time outdoors than girls) or different levels 
of family crowding between the provinces.
In our study the age-specific seroposi-
tive rate rose rapidly from 66.7% at age 
7–11 years to 79.2% at age 12–14 years and 
95.4% at age 15–18 years.
A British study revealed that over 80% 
of children aged 1–2 years did not have 
antibodies to mumps and rubella [9]. This 
is in contrast to our findings that 100% of 
children aged 3–6 years had antibodies to 
mumps. This may be due to the level of pub-
lic health action concerning communicable 
diseases. However, the seropositive rate 
of 100% in day care centres may be over-
reported due to local and seasonal outbreaks 
of mumps.
Among 8th grade students, in a Swiss 
study, 87% of the children tested serop-
ositive for mumps-specific antibodies [10], 
similar to our findings. The prevalence 
of mumps IgG antibodies in a randomly 
selected population of children aged 1–17 
years determined by ELISA showed that 
mumps antibodies were acquired at an early 
age [11]. The peak acquisition rate occurred 
at age 4–5 years; as in our study. In addition, 
the study showed that before age 15 years, 
90% of children had antibodies to mumps 
[11], which is lower than our rate of 95.4%. 
A prevalence study of 333 students at Jor-
dan University showed most of the students 
(93.7%) tested seropositive for mumps an-
tibodies. Mumps occurred in all age groups 
in both sexes and the rate was higher in 
children aged 5–14 years than in adults [12]. 
This is in contrast to our results.
Our review of a number of previous 
studies carried out to detect the optimal age 
for vaccination showed conflicting results, 
suggesting that the findings depend on the 
age of the studied group [3,5,8,9,13,14]. 
For example, an Iranian study suggested 
that vaccination at age 1–5 years is most 
beneficial because 82.3% of subjects were 
seronegative [5]. Another study in India, in-
dicated that, because children are at greatest 
risk of mumps by age 9 years, this age may 
be most beneficial for vaccination [13]. In 
addition a study carried out among infants 
up to 2 years of age concluded that MMR 
vaccination at 12 months instead of 15 
months could reduce the pool of susceptible 
subjects in infancy [14]. A study in England 
on children aged 1–4 years suggested that 
vaccinating children early in the 2nd year of 
life is necessary to eliminate the 3 diseases 
[9]. A Turkish study in Ankara indicated 
the routine health supervision visit at age 
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11–12 years was the ideal time to immu-
nize unvaccinated adolescents [8], whereas 
another study in Izmir suggested that age 
1–10 years was the ideal time to immunize 
unvaccinated children [3]. 
We found a high non-immune status 
among children aged 7–14 years. These 
findings suggest that a large proportion 
of these children (20.5%–33.3%) are at 
risk in our population, and that mumps or 
MMR vaccination at this age may be most 
beneficial. We recommend that mumps 
immunization of these children is important 
until an EPI for mumps with high coverage 
can be sustained.
There was a reported past clinical history 
of mumps in 76.6% of children, confirmed 
serologically in 76.4%. This is similar to 
a previous study which suggests serology 
agreed with the clinical history of the sub-
ject in 82% of cases for mumps [15]. There 
was no clinical history of mumps in 23.4% 
of children, but serology was positive in 
92.4% of these cases. This significant dis-
crepancy may be due to several reasons, 
such as parents’ poor memory, subclinical 
presentation of mumps or self-diagnosis 
and management. Similar to our study, 
another study showed that the frequency of 
seronegative subjects who were reported to 
have had the disease was low (< 8%) [14].
In one study, the reported rate of past 
history of mumps vaccination in students 
without antibodies was 85.0%, and in those 
with low-titre antibody students was 93.8% 
[16]. We found that the past history of 
mumps vaccination was reported at a rate of 
14.5% and 85.7% were seropositive. 
Limitations of the study 
There have been similar studies conducted 
in other provinces [3,4] and this is a regional 
study which cannot be generalized to the 
rest of the population of schoolchildren in 
the Islamic Republic of Iran. This kind of 
study needs to be repeated with a larger, 
more extended sample size to obtain more 
reliable results. Another limitation of this 
study was determining the number of units 
in each stratum, so that for sampling we 
were obliged to use the method of prob-
ability proportional to size. If we had the 
prevalence rate for each stratum then it 
would be possible to compute the samples 
by stratum and this would result in a more 
exact sampling procedure. 
Conclusions
The Iranian EPI targets children at 12 
months and 4–6 years old for MMR vac-
cination. However, based on the results of 
our study, and since a high seronegative rate 
may shift mumps infection to older ages, we 
believe mumps immunization of children 
aged 7–11 years entering guidance school 
is important and that for the next 5 years 
they must be selected as the main group for 
vaccination so that a national mumps vacci-
nation programme with a high coverage can 
be sustained. The routine health supervision 
visit at ages 7–14 years is also an ideal time 
to immunize unvaccinated adolescents. This 
may increase the immunity to the 95% level 
necessary for herd immunity and elimina-
tion of the disease. After that time children 
less than 6 years old may be the only group 
needing mumps vaccination.
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